On February 4, 2020, the Secretary of the US Department of Health and Human Services (DHHS) determined that there was a public health emergency due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). On March 27, 2020, the DHHS secretary declared that circumstances existed to justify the authorization of emergency use of drugs and biologics during the coronavirus disease 2019 (COVID-19) outbreak, pursuant to section 564 of the Federal Food, Drug, and Cosmetic Act.1
Ison MG, Wolfe C, Boucher HW. Emergency Use Authorization of Remdesivir: The Need for a Transparent Distribution Process. JAMA. 2020;323(23):2365–2366. doi:10.1001/jama.2020.8863
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: